About 60 thousand patients with non-valvular atrial fibrillation will have an additional treatment option for the prevention of stroke and systemic embolism.
Based on the results of the state health technology assessment conducted, the Center recommended considering the inclusion of the medicinal product rivaroxaban for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation in the National List of Essential Medicines.
The conclusion has been published on the Center’s website: http://surl.li/stdea
Atrial fibrillation (AF) is the most common chronic cardiac rhythm disorder. The risk of developing AF increases with age. It is expected that over the next 50 years the incidence will become at least twice as high, given the aging of the population.
Therefore, the prevention of complications of atrial fibrillation is important and, together with other cardiovascular diseases, is among the priority areas of healthcare development for 2023-2025, for the primary provision of prevention, early diagnosis and treatment.
The anticoagulant medicinal product rivaroxaban has demonstrated efficacy in the prevention of stroke and embolism in patients with non-valvular atrial fibrillation, not inferior to traditional medicines such as warfarin. The overall efficacy and safety of this medicine will help improve the quality of treatment for patients with atrial fibrillation.
